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Treatment of Femoropopliteal In-Stent Restenosis
With Paclitaxel-Eluting Stents
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Elias Noory, MD,* Ulrich Beschorner, MD,* Patricia L. Kultgen, PHD,§
Aljoscha Rastan, MD*
Bad Krozingen and Rosenheim, Germany; Stanford, California; and West Lafayette, Indiana
Objectives This study sought to evaluate the outcomes of drug-eluting stent treatment for femo-
ropopliteal in-stent restenosis (ISR).
Background ISR after femoropopliteal interventions is an increasing problem. Although the role of
drug-eluting stents in the treatment of coronary ISR is well deﬁned, no published studies have ex-
amined drug-eluting stents in the treatment of femoropopliteal ISR.
Methods This study examines 108 patients with 119 ISR lesions who were enrolled in the ZILVER-
PTX single-arm study, a prospective, multicenter clinical trial of 787 patients. All patients were
treated with paclitaxel-eluting nitinol stents.
Results Mean patient age was 68.3  9.4 years; 61.1% of patients were men. Mean lesion length
was 133.0  91.7 mm; 33.6% of lesions were 150 mm long and 31.1% of lesions were totally oc-
cluded. Procedural success was achieved in 98.2% of lesions with 2.1  1.2 stents placed per lesion.
Primary patency was 95.7% at 6 months and 78.8% at 1 year. Freedom from target lesion revascular-
ization was 96.2% at 6 months, 81.0% at 1 year, and 60.8% at 2 years. Forty patients experienced
major adverse events, exclusively target lesion revascularization. Before treatment, 81.1% of patients
had Rutherford scores 3; at 2 years, 60.9% of patients had Rutherford scores 1. Both ankle bra-
chial index and walking impairment questionnaire scores signiﬁcantly improved following treatment.
The 1-year fracture rate of stents used in ISR lesions was 1.2%. No signiﬁcant risk factors associated
with loss of patency were identiﬁed.
Conclusions Treatment of femoropopliteal ISR with paclitaxel-eluting stents results in favorable acute,
midterm, and long-term outcomes. (Zilver PTX Global Registry [ZILVER-PTX]; NCT01094678) (J Am
Coll Cardiol Intv 2013;6:274–81) © 2013 by the American College of Cardiology Foundation
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275Stent placement has become a standard treatment modality
in peripheral vascular interventions. Randomized controlled
studies using second-generation stents have shown superior
technical and clinical outcomes over percutaneous translu-
minal angioplasty (PTA) in lesions of the superficial femoral
and proximal popliteal arteries (1–5). Therefore, the Trans-
Atlantic Inter-Society Consensus (TASC) II guidelines (6)
favor endovascular approaches over surgical revasculariza-
tion in femoropopliteal lesions15 cm in length. However,
in-stent restenosis (ISR) has been reported in 19% to 37%
of femoropopliteal lesions treated with bare-metal stents
within 1 year of treatment (2,3,5,7–10). Moreover, the risk
of ISR increases with increasing lesion length (10–12).
See page 290
The treatment of ISR in the femoropopliteal artery is 1 of
the major remaining challenges of endovascular therapy
because treatment modalities such as PTA and cutting
balloon angioplasty have failed to provide acceptable mid-
term results (13,14). To avoid bypass surgery, alternative
endovascular approaches are needed to achieve durable
long-term results in the treatment of ISR, particularly in
long lesions.
Drug-eluting stents, which are available globally, and
drug-eluting balloons, which are available in Europe and
Latin America, are established therapies for the treatment of
coronary ISR (15–17) and may also be useful in the
treatment of peripheral ISR. The ZILVER-PTX single-
arm study investigated the performance of a paclitaxel-
eluting nitinol stent in the superficial femoral and the
above-the-knee popliteal arteries (18). This study had very
broad inclusion criteria, which allowed for the treatment of
patients with femoropopliteal ISR. Here we report the
outcomes of patients with ISR lesions who were treated
within the ZILVER-PTX single-arm study and compare
the results with the current literature.
Methods
The ZILVER-PTX single-arm study is a prospective,
multicenter clinical trial that enrolled 787 patients in Eu-
rope, Canada, and Korea between April 2006 and June
2008. A detailed description of the study and the 1-year
outcomes for the entire cohort, as well as limited, prelimi-
nary results for the ISR subgroup, have been previously
published (18,19). Approval was obtained from each site’s
ethics committee, and patients provided written informed
consent before enrollment. Patients were eligible for the
study if they had 1 de novo or restenotic lesions of the
above-the-knee segment of the femoropopliteal artery with
50% diameter stenosis and baseline clinical symptoms
classified as Rutherford category 2. Patients could have
multiple lesions requiring treatment, a history of prior stent rplacement within the lesion, bilateral lesions requiring
treatment, and lesions of unlimited length. This report
describes the 2-year results for patients who were treated for
ISR. Patients treated for multiple lesion types (e.g., both de
novo and ISR) were excluded from this analysis.
Study device. Patients were treated with the Zilver PTX
drug-eluting stent (Cook Medical, Bloomington, Indiana),
a nitinol stent with a polymer-free paclitaxel coating at 3
g/mm2 dose density. Pharmacokinetics of the device have
been previously described (20). Available stents were 6 to 10
mm in diameter and 20 to 80 mm in length. Although
lesions could be of unlimited length, the protocol specified
planned treatment with a maximum of 4 Zilver PTX stents
per patient. Placement of bare Zilver stents was allowed if
additional stents were required. Pre- and post-dilation were
performed at the interventionalist’s discretion.
Medication. Clopidogrel was administered at least 24 h before
the procedure or as a loading dose during the procedure.
Following treatment, clopidogrel therapy was continued for
60 days and aspirin therapy was continued indefinitely.
Heparin was administered periprocedurally if heparinization
was part of an institution’s standard practice. Administered
doses of all anticoagulants were
based on the standard practice at
each institution.
Pre- and post-procedural diag-
nostic workup. Prior to the pro-
edure and at 1-, 6-, 12-, and
4-month follow-ups, patient-
erceived walking speed and dis-
ance were assessed using the
alking Impairment Question-
aire (21), symptoms were categorized using the
utherford-Becker classification, and lower limb hemody-
amics were assessed with the ankle-brachial index. Stent
ntegrity was assessed by radiograph within 3 days after the
rocedure and at 6 and 12 months. Target lesion patency
as assessed by angiography immediately after stent im-
lantation. Duplex ultrasound was conducted within 3
usiness days of the procedure and at 6- and 12-month
ollow-up. Per protocol, duplex ultrasound assessment of
esion patency was not required after 12-month follow-up.
estenosis was confirmed by angiography before target
esion revascularization (TLR).
Deﬁnitions. Procedural success was defined as 30% resid-
al diameter stenosis following stent placement. Patency
as defined as 50% diameter stenosis, including the
egion within 5 mm proximal and/or distal to the target
esion as assessed by angiography or duplex ultrasound. For
his analysis, a peak systolic velocity ratio 2.5 was used as
he patency threshold. Clinically driven TLR was defined as
reintervention performed for 50% diameter stenosis
ithin 5 mm of the target lesion after documentation of
Abbreviations
and Acronyms
EFS  event-free survival
ISR  in-stent restenosis
PTA  percutaneous
transluminal angioplasty
TLR  target lesion
revascularizationecurrent clinical symptoms of peripheral artery disease
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276following the initial procedure. Event-free survival (EFS)
was defined as freedom from major adverse events (e.g.,
procedure- or device-related death, clinically driven TLR,
target limb ischemia requiring bypass surgery or amputa-
tion, and surgical repair of the target vessel) and freedom
from worsening of Rutherford classification by2 classes or
to class 5 or 6.
Statistics. Continuous variables were summarized with
means and standard deviations; categorical variables were
summarized with counts and percentages. As appropriate,
the number of observations is the number of patients,
treated limbs, or implanted stents. Kaplan-Meier analyses
were performed to estimate patency, freedom from TLR,
and EFS over time. A paired t test was used to compare
pre-procedure ankle brachial index and Walking Impair-
ment Questionnaire values to the follow-up values. A
generalized estimating equation model was used to evaluate
the association between potential risk factors (e.g., diabetes,
lesion length, smoking history, Rutherford classification,
occlusion, calcification, lesion location, patent runoff vessels,
fracture in prior stent, type of prior stent, days from previous
intervention, number of previous interventions, proximal
reference vessel diameter, and percentage of diameter ste-
nosis) and 12-month patency; p values 0.05 were consid-
ered significant. Data were analyzed using SAS software
(version 9.3, SAS Institute Inc., Cary, North Carolina).
Results
One hundred and eight patients with 119 ISR lesions of the
femoropopliteal artery were treated with Zilver PTX drug-
eluting stents. Most patients were male (61.1%), hyperten-
sive (84.3%), hypercholesterolemic (74.1%), and had a
history of smoking (81.5%) (Table 1). Mean lesion length
was 133.0 91.7 mm and 33.6% (40 of 119) of lesions were
150 mm long (Table 2). Most ISR lesions had little to no
calcification (68.9%, 82 of 119); however, 31.1% (37 of 119)
Table 1. Patient Demographics and Comorbidities
Demographic Category
Patients With ISR
Lesions (n  108)
Age, yrs 68.3 9.4
Men 61.1 (66)
Body mass index 26.8 4.1*
Diabetes 38.9 (42)
Hypercholesterolemia 74.1 (80)
Hypertension 84.3 (91)
Carotid disease 11.1 (12)
Renal disease 18.5 (20)
Congestive heart failure 4.6 (5)
Present or former smoker 81.5 (88)
Values aremean SDor% (n). *Meanbodymass index is based ondata available from105 of 108
patients.ISR in-stent restenosis.of the ISR lesions were totally occluded before treatment.
Of the 119 ISR lesions, 8.4% (10 of 119) had severely
fractured stents (i.e., type III or IV fracture, complete
transection of stent) before Zilver PTX treatment, 22.7%
(27 of 119) had been previously treated within the last 6
months, and 51.3% (61 of 119) had undergone 2 previous
interventions.
Procedural outcomes. Procedural success (i.e., 30% re-
stenosis following stent placement) was achieved in
98.2% (112 of 114) of ISR lesions. Most patients were
treated for a single lesion (91.7%, 99 of 108); 7 patients
were treated for 2 lesions; and 2 patients were treated for
3 lesions. On average, 2.1  1.2 stents were placed in
Table 2. Baseline Lesion Characteristics
Characteristic ISR Lesions (n  119)
Length, mm 133.0 91.7
70 63.0 (75)
150 33.6 (40)
Proximal reference vessel diameter, mm 5.6 0.7
Distal reference vessel diameter, mm 5.3 0.8
Minimum lumen diameter, mm 0.7 0.7*
Diameter stenosis, % 87.0 12.4*
TASC I class
A 22.7 (27)
B 28.6 (34)
C 26.9 (32)
D 16.0 (19)
Not assessed 5.9 (7)
Total occlusion 31.1 (37)
Calciﬁcation
Severe 12.6 (15)
Moderate 18.5 (22)
Little 33.6 (40)
None 35.3 (42)
Lesion location
Proximal SFA 23.5 (28)
Proximal SFA/distal SFA 29.4 (35)
Proximal SFA/distal SFA/popliteal 6.7 (8)
Distal SFA 32.8 (39)
Distal SFA/popliteal 5.9 (7)
Popliteal 1.7 (2)
Previous interventions, n
1 48.7 (58)
2 24.4 (29)
3 16.8 (20)
4–8 10.1 (12)
6 months since last intervention 22.7 (27)
Type III or IV fracture in previously placed stents 8.4 (10)
Values aremean SDor% (n). *Mean values forminimum lumendiameter anddiameter stenosis
are based on available data for 118 of 119 lesions.
ISR in-stent restenosis; SFA superficial femoral artery; TASC I Trans-Atlantic Inter-Society
Consensus 2000.each lesion.
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277Lesion patency, TLR, and event-free survival. The Kaplan-
eier estimate of primary patency was 95.7% at 6 months
nd 78.8% at 12 months (Fig. 1). Per protocol, duplex
ltrasound assessments of patency were not required after
2-month follow-up; however, clinical follow-up continued
hrough 24 months. Kaplan-Meier estimates of freedom
rom clinically driven TLR at 6 and 12 months were similar
o the patency estimates over the same period. Specifically,
he Kaplan-Meier estimate of freedom from TLR was
6.2% at 6 months, 81.0% at 12 months, and 60.8% at 24
onths (Fig. 2).
During the course of the study, major adverse events were
xperienced by 40 patients treated for ISR lesions. Thirty-
ight patients each underwent a single TLR, and 2 patients
ach underwent 2 TLR; 50% of the revascularizations
ccurred within 12 months of treatment. No amputations
r deaths occurred. Because all patients who failed EFS
xperienced a TLR, Kaplan-Meier estimates of freedom
rom EFS are identical to estimates of freedom from
LR (Fig. 3).
Multivariate analysis of risk factors for recurrent ISR. A
eneralized estimating equation model was used to evaluate
he association between potential risk factors and loss of
atency; however, no significant predictors of recurrent ISR
ere identified (Table 3).
Clinical outcomes. In addition to establishing vessel pa-
ency, treatment of ISR lesions with the Zilver PTX stent
Figure 1. Kaplan-Meier Estimates of Primary Patency
For this subgroup analysis, peak systolic velocity ratio 2.5 was used as
the threshold for patency. The vertical bars at 6 and 12 months represent
95% conﬁdence intervals. The corresponding life table is included.lso provided clinical benefit to patients. Before treatment,1.1% (86 of 106) of patients had Rutherford scores 3.
fter treatment, 63.2% (62 of 98) of patients at 12 months
nd 60.9% (53 of 87) of patients at 24 months had
utherford scores 1. Significant improvements in limb
emodynamic status, as assessed by ankle brachial index,
nd in patient-perceived walking speed, walking distance,
nd climbing were also observed (Table 4).
Stent fracture rates. Based on x-ray data collected at the
12-month follow-up, the fracture rate of Zilver PTX stents
used in ISR lesions was 1.2% (3 of 257).
Discussion
To date, the ZILVER-PTX single-arm study is the largest
trial to prospectively investigate endovascular treatment of
femoropopliteal ISR lesions. Of the 787 treated patients,
108 patients were treated for 119 ISR lesions. Treatment of
ISR lesions with a paclitaxel-eluting stent had a primary
patency estimate of 95.7% at 6 months and 78.8% at 12
months. Freedom from clinically driven TLR at 6 and 12
months was similar to the patency estimates over the same
period. Compared with most other published reports of
femoropopliteal ISR lesion treatment (13,14,22–27), treat-
Figure 2. Kaplan-Meier Estimates of Freedom From TLR
Target lesion revascularization (TLR) was deﬁned as a reintervention per-
formed for 50% diameter stenosis (conﬁrmed by angiography) within 5
mm proximal and/or distal to the target lesion after documentation of
recurrent clinical symptoms of peripheral artery disease following the initial
procedure. TLR procedures included percutaneous reintervention, surgical
bypass, and surgical repair of the target vessel. The vertical bars at 6, 12,
and 24 months represent 95% conﬁdence intervals. The corresponding life
table is included. TLR  target lesion revascularization.
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278ment of ISR lesions with paclitaxel-eluting stents resulted in
higher midterm rates of primary patency (Table 5).
Notably, this is the first prospective study to report 2-year
results for endovascular treatment of femoropopliteal ISR
lesions. Although patency data were only systematically
collected through 12-month follow-up, data on TLR, EFS,
and other clinical outcomes were collected through 2 years.
In this difficult-to-treat patient population, freedom from
clinically driven TLR was 60.8% at 2 years. Although
revascularization was required for some patients, the TLR
procedures were predominantly percutaneous interventions
(88%, 37 of 42) and no patients underwent amputation.
These promising results are likely due to several advan-
tageous features of the Zilver PTX stent, a self-expanding
nitinol stent with a polymer-free paclitaxel coating. Local
delivery of paclitaxel, a drug that disrupts normal microtu-
bule function, may prevent neointimal hyperplasia by inhib-
iting smooth muscle cell migration, proliferation, and ex-
tracellular matrix secretion (28). Because low doses of
paclitaxel can inhibit smooth muscle proliferation without
inhibiting endothelial cell proliferation (29), local paclitaxel
delivery may inhibit restenosis after endovascular interven-
tions without preventing re-endothelialization. This mode
of action may reduce the rate of subacute stent thrombosis.
Figure 3. Kaplan-Meier Estimates of EFS
EFS was deﬁned as freedom from major adverse events (e.g., procedure- or
device-related death, clinically driven TLR, target limb ischemia requiring
bypass surgery or amputation, and surgical repair of the target vessel) and
freedom from worsening of Rutherford classiﬁcation by 2 classes or to
class 5 or 6. The vertical bars at 6, 12, and 24 months represent 95% con-
ﬁdence intervals. The corresponding life table is included. EFS  event-
free survival.Additionally, unlike other drug-eluting stents, the ZilverPTX stent has no polymers, binders, or carriers within the
drug coating that might elicit potential inflammatory or
thrombotic reactions. Moreover, placement of a second
stent layer does not appear to adversely affect the integrity of
the Zilver PTX stent as only 1.2% (3 of 257) of stents used
in this study had detectable fractures at 12 months.
Few controlled prospective data are published about
endovascular treatment of femoropopliteal ISR lesions.
Dick et al. (13) performed a pilot trial randomly comparing
PTA with cutting balloon angioplasty in femoropopliteal
ISR lesions with a mean length of 8 cm. At 6 months, only
27% of PTA-treated lesions and 35% of cutting balloon-
treated lesions were patent. In this small study, neither
angioplasty method provided acceptable short-term out-
comes. In a larger retrospective study by Tosaka et al. (14)
that included 133 patients, PTA treatment of femoropop-
liteal ISR lesions resulted in 69% patency for stenosed
lesions at 12 months; however, only 23% of treated occluded
lesions were patent at 12 months.
The use of debulking strategies, such as laser atherec-
tomy, directional atherectomy, and mechanical throm-
bectomy, for treatment of femoropopliteal ISR has been
investigated in several case series (Table 5) (22–27,30,31).
Supplemental PTA, stent, and/or stent-graft placement
were often used adjunctively in these reported experiences.
Most of the studies were small (treating 20 to 40 patients)
and have reported 1-year primary patency rates ranging
from 19% to 58%. Compared with available data on PTA
alone or debulking strategies, the results of the ZILVER-
PTX single-arm study suggest that treatment of femoropo-
pliteal ISR lesions with paclitaxel-eluting stents is quite
promising.
The treatment of femoropopliteal ISR with endovascular
brachytherapy has also been examined. In a retrospective
case series, 90 consecutive patients underwent angioplasty
and subsequent brachytherapy with liquid beta-emitting
Table 3. Multivariate Analysis of Risk Factors for Recurrent ISR
Potential Risk Factor p Value
Diabetes 0.34
Lesion length 0.12
Smoking history 0.75
Rutherford classiﬁcation 0.27
Total occlusion 0.80
Extent of calciﬁcation 0.18
Lesion location 0.67
Number of patent runoff vessels 0.77
Fracture in prior stent 0.55
Type of prior stent 0.53
Days from previous intervention to Zilver PTX treatment 0.70
Number of previous interventions 0.24
Proximal reference vessel diameter 0.52Percentage of diameter stenosis 0.34
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279rhenium Re 188 (32). Similar to the results of the
ZILVER-PTX single-arm study, primary patency was
95.2% at 6 months and 79.8% at 12 months. However, the
utility of brachytherapy may be limited due to the time-
consuming nature of the procedure, complex radiation
Table 4. Clinical Outcomes
Clinical Measure Pre-Procedure
ABI per limb 0.60 0.28 (100) 0
Median Rutherford score 3 (106)
Walking speed score 33 28 (91)
Walking distance score 27 26 (93)
Climbing score 37 29 (86)
Values are mean SD (n), unless otherwise noted. Walking and climbing scores were obtained from
Patient responses are weighted and the weighted average is reported with amaximum possible sco
paired t test.
ABI ankle brachial index.
Table 5. Comparison of Published Primary Patency and TLR Rates Followin
Study/First Author
(Ref. #) Treatment
Patients,
n
Lesions,
n
Les
ZILVER-PTX single-arm
study
Zilver PTX stent 108 119 1
Tosaka et al. (14) PTA 133 133 91
s
198
o
Dick et al. (13) PTA 22 22
Cutting balloon angioplasty 17 17
Shammas et al. (30) Directional atherectomy;
adjunctive PTA and stenting
in some cases
41 41 1
Trentmann et al. (24) Directional atherectomy;
adjunctive PTA and stenting
for some cases
33 35 1
Zeller et al. (26) Directional atherectomy — 43 1
Shammas et al. (31) Laser atherectomy  PTA;
adjunctive stent
40 — 2
Laird et al. (22) Laser atherectomy, PTA, and
heparin-coated stent graft
27 — 2
Yeo et al. (25) Laser atherectomy, angioplasty,
excisional atherectomy,
and/or cryoplasty
20 22 limbs 1
Silingardi et al. (23) Rotational thrombectomy
and PTA
32 32 limbs†
Zeller et al. (27) Rotational thrombectomy
and PTA
40 40
Werner et al. (32) PTA and brachytherapy 90 — 2
Stabile et al. (33) Paclitaxel-eluting balloon;
adjunctive stent and laser
atherectomy
39 —
For this analysis of the ZILVER-PTX single-arm study, PSVR2.5 was used as the patency threshold. P
et al. (26),Werner et al. (32), andStabile et al. (33); and2.0byYeoet al. (25) andLairdet al. (22). Tosak
et al. (23) and Zeller et al. (27) did not provide a PSVR patency threshold in their reports. Dashes indic
iliac and 26 femoropopliteal arteries. ‡Mean follow-up of 13.1 months (range 3 to 45 months).ISR in-stent restenosis; PSVR peak systolic velocity ratio; PTA percutaneous transluminal angioplasafety measurements, and staffing requirements. Addition-
ally, patients with stent fracture were excluded from brachy-
therapy treatment due to the potential risk of balloon
rupture. In contrast, patients with stent fracture may be
treated with the Zilver PTX stent.
onths 12 Months 24 Months
.25* (102) 0.87 0.28* (99) 0.84 0.22* (87)
(97) 0 (98) 1 (87)
0* (94) 58 32* (92) 63 32* (87)
4* (99) 68 33* (95) 63 37* (88)
3* (94) 65 31* (92) 67 34* (83)
alking Impairment Questionnaire, a validated measure of patient-perceived walking performance.
0% in each category. *Value differed significantly from pre-procedure (p 0.001), as calculated by
atment of Femoropopliteal ISR
ngth,
Primary Patency Freedom From TLR
6 Months 12 Months 24 Months 6 Months 12 Months 24 Months
2 96% 79% — 96% 81% 61%
r
s
— 69% 48% — — —
or
ns
— 23% 15% — — —
5 27% — — 64% — —
4 35% — — 59% — —
9 — — — — 66% —
1 68%* 25%* — — — —
11 — 54% 49% at 18
months
— 53% 51% at 18
months
04 — — — — 49% —
03 — 48% — — 83% —
13 55% 48% — — 77% —
75% 58% — — 47%‡ —
46% 19% — — — —
22 95% 80% — — — —
9 — 92% — — 92% —
was defined as duplex ultrasound PSVR2.5 by Trentmann et al. (24);2.4 by Dick et al. (13), Zeller
14) definedpatencyas2.4PSVRbyduplexultrasoundor50%stenosis by angiography. Silingardi
a were unavailable. *Data only available for 25 lesions at 6months and 17 lesions at 12months.†Six6 M
.87 0
0
62 3
66 3
66 3
the W
re of 10g Tre
ion Le
mm
33 9
67 fo
tenose
 62 f
cclusio
74 6
84 7
26 7
41 8
31 1
10 1
07 1
32 1
160
—
46 1
83 7
atency
aet al. (
ate datsty; TLR target lesion revascularization.
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280There is also much interest in the potential role of
drug-eluting balloons in the treatment of femoropopliteal
ISR. One small study of 39 patients reported an impressive
1-year primary patency rate of 92.1% (33). However, 10% of
patients also underwent laser-mediated debulking, and 10%
of patients required bailout stent placement to treat flow-
limiting dissection. Therefore, the patency rate cannot be
attributed to the effects of the drug-eluting balloon alone.
Additional investigation is necessary, and several ongoing
randomized controlled trials are comparing drug-eluting
balloons to uncoated balloons for the treatment of femo-
ropopliteal ISR.
Previously, Tosaka et al. (14) identified total occlusion
and reference vessel diameter as independent, predictive
factors for recurrent ISR following PTA treatment of
femoropopliteal ISR. Additionally, in a study that treated
femoropopliteal restenosis with angioplasty and stenting,
treatment within 180 days of the initial endovascular
intervention was identified as a significant predictor for
recurrent restenosis (34). In contrast, of the 14 risk
factors considered (Table 3), none was predictive for
recurrent ISR following treatment with a paclitaxel-
eluting stent in this study.
Study limitations. This study lacked a control group. How-
ver, the 12-month patency rate for the ISR lesions was only
lightly lower than the patency rate for the entire ZILVER-
TX single-arm trial (78.8% vs. 86.2%), which included
6.7% de novo lesions (18). Furthermore, all angiography
nd duplex ultrasound data are self-reported by sites, and no
ore laboratory was used to standardize data. Although
hese results are promising, head-to-head comparative stud-
es are necessary to determine whether the Zilver PTX stent
s more effective than other endovascular modalities for
reatment of femoropopliteal ISR.
Future perspectives. Several ongoing randomized con-
trolled trials are comparing drug-eluting balloons to un-
coated balloons for treatment of femoropopliteal ISR
(ISAR-PEBIS [Paclitaxel Eluting Balloon and Conven-
tional Balloon for In-Stent Restenosis of the Superficial
Femoral Artery], FAIR [Femoral Artery In-Stent Resteno-
sis Trial], PACUBA I [Paclitaxel Balloon Versus Standard
Balloon in In-Stent Restenoses of the Superficial Femoral
Artery], COPA CABANA [Cotavance Paclitaxel-Coated
Balloon Versus Uncoated Balloon Angioplasty for Treat-
ment of In-stent Restenosis in SFA and Popliteal Arteries],
PLAISIR [Paclitaxel Eluting Balloon Application in SFA
In-Stent Restenosis], and DEBATE-ISR [Drug Eluting
Balloon in Peripheral Intervention for In-Stent Resteno-
sis]). Additionally, other trials are investigating the perfor-
mance of the Viabahn endoprosthesis (RELINE [Gore
Viabahn Versus Plain Old Balloon Angioplasty for Super-
ficial Femoral Artery Restenosis]), drug-coated balloons
with and without prior photoablation (PHOTOPAC [Pho-
toablative Atherectomy Followed by a Paclitaxel-CoatedBalloon to Inhibit Restenosis in In-Stent Femoro-Popliteal
Obstructions]), laser atherectomy with PTA (EXCITE ISR
[Randomized Study of Laser and Balloon Angioplasty
Versus Balloon Angioplasty to Treat Peripheral In-Stent
Restenosis]), and photoablation alone (PATENT [Photo-
Ablation using the TURBO-Booster and Excimer Laser for
In-stent Restenosis Treatment]) for treatment of femoropo-
pliteal ISR.
Conclusions
The subcohort of the ZILVER-PTX single-arm trial is to
date the largest prospective investigation of the midterm
and long-term outcomes of femoropopliteal ISR lesions
following endovascular treatment. Stent-in-stent placement
of a paclitaxel-eluting stent results in promising 1- and
2-year clinical outcomes with a low stent fracture rate.
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